Hydrogels and uses thereof
Provided herein are polymers of Formula (I), and pharmaceutically acceptable salts, co-crystals, tautomers, stereoisomers, and isotopically labeled derivatives thereof, compositions, and formulations thereof. The polymers described herein are biocompatible, non-toxic, water compatible, and operationally simple to formulate. Also provided are methods and kits involving the polymers described herein (e.g., methods of using polymers described herein for delivering agents (e.g., for therapeutic, diagnostic, prophylactic, imaging, ophthalmic, intraoperative, or cosmetic use) to a subject, cell, tissue, or biological sample, as part of materials (e.g., biodegradable materials, biocompatible materials, wound dressing (e.g., bandages), drug depots, coatings), or as scaffolds for tissue engineering. Provided are methods for synthesizing the polymers described herein, and polymers described herein synthesized by the synthetic methods described herein.
1. A polymer of Formula (I):
or a pharmaceutically acceptable salt, co-crystal, tautomer, stereoisomer, or isotopically labeled derivative thereof,
wherein:
each A independently is an amine; and
each n independently is between 10-150.
2. The polymer, pharmaceutically acceptable salt, co-crystal, tautomer, stereoisomer, or isotopically labeled derivative thereof, of claim 1 , wherein the amine A is of the Formula (I-A):
wherein:
each R independently is H, optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl; and
each Z independently is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, or of the Formula (I-Z):
wherein each Al independently is an amine, and each n independently is between 10-150.
3. The polymer, pharmaceutically acceptable salt, co-crystal, tautomer, stereoisomer, or isotopically labeled derivative thereof, of claim 2 , wherein at least one instance of Z is of the Formula (I-Z).
4. A method of preparing a polymer, pharmaceutically acceptable salt, co-crystal, tautomer,stereoisomer, or isotopically labeled derivative thereof, of claim 2 , comprising:
reacting a tetra-arm polyethylene glycol alkynoate compound of Formula (A):
or a pharmaceutically acceptable salt, co-crystal, tautomer, stereoisomer, or isotopically labeled derivative thereof,
with an amine of Formula (B):
or a pharmaceutically acceptable salt, co-crystal, tautomer, stereoisomer, or isotopically labeled derivative thereof,
wherein:
each n independently is between 10-150;
each R independently is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl;
each Z independently is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted slkynyl, or the Formula (I-Z):
wherein each A 1 independently is an amine;
under suitable conditions,
such that a polymet of claim 2 is formed.
5. The polymer, pharmaceutically acceptable salt, co-crystal, tautomer, stereoisomer, or isotopically labeled derivative thereof, of claim 1 , wherein the polymer is of the formula:
or a pharmaceutically acceptable salt, co-crystal, tautomer, stereoisomer, or isotopically labeled derivative thereof;
wherein each instance of n is between 25-135.
6. The polymer of claim 1 , wherein the polymer is a hydrogel.
7. The polymer of claim 1 , wherein the polymer forms a hydrogel.
8. A composition comprising a polymer, pharmaceutically acceptable salt, co-crystal, tautomer, stereoisomer, or isotopically labeled derivative thereof, of claim 1 .
9. A kit comprising:
a polymer, pharmaceutically acceptable salt, co-crystal, tautomer, stereoisomer, or isotopically labeled derivative thereof, of claim 1 , or a composition thereof; and
instructions for administering to a subject or contacting a cell, tissue, or biological sample with the polymer or the composition.
10. a composition comprising a polymer of claim 1 , or a pharmaceutically acceptable salt, co-crystal, tautomer, stereoisomer, or isotopically labeled derivative thereof.
11. The composition of claim 10 , wherein the agent is a therapeutic agent.
12. The composition of claim 11 , wherein the therapeutic agent is a small molecule, nucleic acid, protein, peptide, polynucleotide, biologic.
13. A scaffold for tissue engineering comprising a composition of claim 8 .
14. The scaffold of claim 13 , wherein the scaffold comprises cells, growth factors, proteins, peptides, or cell binding domains.
15. The composition of claim 10 , further comprising an agent.
16. A particle comprising a polymer of claim 1 .
17. A method of delivering an agent to a subject in need thereof, the method comprising administering to the subject an effective amount of a polymer of claim 1 , or a composition thereof.
18. A method of delivering an agent to a subject in need thereof, the method comprising administering to the subject an effective amount of a composition of claim 15 .
19. A method of delivering an agent to a cell, tissue, or biological sample, the method comprising contacting the cell, tissue, or biological sample with an effective amount of a composition of claim 15 .
20. The composition of claim 15 , wherein the agent is a cosmetic agent.
21. The composition of claim 15 , wherein the agent is a diagnostic agent.
22. The composition of claim 15 , wherein the agent is a prophylactic agent.
23. A method of preparing a polymer, pharmaceutically acceptable salt, co-crystal, tautomer, stereoisomer, or isotopically labeled derivative thereof, comprising:
reacting a protein derivatized with an electrophile, a carbohydrate derivatized with an electrophile, or a tetra-arm polyethylene glycol alkynoate compound of Formula (A):
or a pharmaceutically acceptable salt, co-crystal, tautomer, stereoisomer, or isotopically labeled derivative thereof,
with an amine selected from the group consisting of: linear amines, branched amines, polyamines, cyclic amines, matrix metalloproteinase (MMP) degradable amines, redox sensitive amines, photocleavable amines, and
a compound of Formula (B):
or a pharmaceutically acceptable salt, co-crystal, tautomer, stereoisomer, or isotopically labeled derivative thereof,
wherein:
each n independently is between 10-150;
each R independently is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl;
each Z independently is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, or of the Formula (I-Z):
wherein each Al independently is an amine, and each n independently is between 10-150;
under suitable conditions.